alendronate has been researched along with Heart Disease, Ischemic in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banai, S | 1 |
| Finkelstein, A | 1 |
| Almagor, Y | 1 |
| Assali, A | 1 |
| Hasin, Y | 1 |
| Rosenschein, U | 1 |
| Apruzzese, P | 1 |
| Lansky, AJ | 1 |
| Kume, T | 1 |
| Edelman, ER | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous Liposomal Alendronate Infusion in Subjects Undergoing Bare Metal Coronary Stent Implantation[NCT00739466] | Phase 2 | 226 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alendronate and Heart Disease, Ischemic
| Article | Year |
|---|---|
Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial.
Topics: Administration, Intravenous; Alendronate; Coronary Angiography; Coronary Restenosis; Dose-Response R | 2013 |